Payment overview · 2025
General Payments
$745.89
50 reported records · 12 companies
Healthcare provider profile · identity verified
John Schinner, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · POLAND, OH · NPI 1619284171
Verified facts
What the public records show
CMS Open Payments records show John Schinner, M.D. received $745.89 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $291.54 | 39.1% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $157.66 | 21.1% | 17 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.05 | 9.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.03 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.79 | 5.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.00 | 4.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.09 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.48 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.90 | 2.3% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.43 | 2.2% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $15.83 | 2.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.09 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $745.89 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $157.66 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.53 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $116.00 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.41 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $79.57 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $78.09 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $71.58 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 110 |
| Lisinopril | Lisinopril | 310 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 71 |
| Losartan Potassium | Losartan Potassium | 193 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 49 |
| Omeprazole | Omeprazole | 169 | 54 |
| Metformin Hcl | Metformin Hcl | 150 | 44 |
| Farxiga | Dapagliflozin Propanediol | 135 | 26 |
| Sertraline Hcl | Sertraline Hcl | 115 | 38 |
| Alendronate Sodium | Alendronate Sodium | 113 | 34 |
| Metformin Hcl Er | Metformin Hcl | 105 | 27 |
| Gabapentin | Gabapentin | 103 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 36 |
| Simvastatin | Simvastatin | 88 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 25 |
| Eliquis | Apixaban | 76 | 24 |
| Trazodone Hcl | Trazodone Hcl | 75 | 24 |
| Furosemide | Furosemide | 65 | 27 |
| Prednisone | Prednisone | 61 | 54 |
| Carvedilol | Carvedilol | 60 | 21 |
| Jardiance | Empagliflozin | 59 | 17 |
| Potassium Chloride | Potassium Chloride | 56 | 19 |
| Allopurinol | Allopurinol | 55 | 18 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 36 |
| Ozempic | Semaglutide | 53 | 12 |
| Famotidine | Famotidine | 52 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Trulicity | Dulaglutide | 48 | 13 |
| Buspirone Hcl | Buspirone Hcl | 46 | 15 |
| Meloxicam | Meloxicam | 45 | 19 |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Valsartan | Valsartan | 43 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 18 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.89 · 50 records | ABBVIE INC. | CREON, Doc Band, ELIQUIS, ID NOW INSTRUMENT, JARDIANCE, JASCAYD, KEVEYIS, Korlym, LINZESS, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, Tascenso ODT, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error